Finding
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1
Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug
Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China
Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns
Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy
Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment
Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis
GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study
GLP-1, Obesity-Related Cancers, Diabetes Patients, Cancer Prevention, Weight Loss
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option
Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options
Pressure Points: Understanding Their Role in Self-Defense and Health
Pressure Points, Self-Defense, Knockout Techniques, Acupressure, Health Benefits, Pain Relief